FuelCell Energy Inc vs Heron Therapeutics Inc — how do they compare? FuelCell Energy Inc trades at $17.35 (market cap $1.62B), while Heron Therapeutics Inc trades at $0.51 (market cap $84.50M). The key difference: FuelCell Energy Inc is far larger — about 19.2× Heron Therapeutics Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | HRTX | |
|---|---|---|
Market Cap | $1.62B | $84.50M |
Sector | Industrials | Health |
52-Week High | $36.01 | $2.02 |
52-Week Low | $3.92 | $0.39 |
Enterprise Value | $1.47B | $182.40M |
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.35, down 18.74% over 24 hours, reflecting recent volatility. The stock shows a bearish technical signal with support at $17 and resistance at $21. Fundamentally, the company reported a net loss of $187.90 million on $158.16 million revenue in 2025, with negative profit margins persisting. Recent news highlights a partnership with Siemens for scalable fuel cell solutions and a $225 million stock offering that caused dilution concerns. Analyst consensus is mixed with a $20.75 price target.
FCEL presents high-risk growth potential driven by AI data center energy demand and strategic partnerships, but faces significant challenges including consistent losses, cash burn, and shareholder dilution. The stock's outlook hinges on execution of commercial projects and path to profitability, with substantial downside risk if growth catalysts fail to materialize.
Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.
HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.
Trailing returns across standard periods
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →